PHARMA - 9 December 2024 🔊Biocon Biologics' Yesintek Receives Green Light From FDA YESINTEK™ is approved for use in Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a biosimilar option ...

Weekly Roundup - PHARMA - 9 December 2024

www.linkedin.com/pulse/pharma...

➡ kstrategyand.com/pharma-news

#BioconBiologics #Yesintek #BPZE1 #Roche #SanDiegoBiotech #PTC #Novartis #HuntingtonsDiseaseDrug #GSK #Pharma #Healthcare #ClinicalTrials #Humanteconomy #Humantec